The latest price target for Cognition Therapeutics (NASDAQ:CGTX) was reported by B. Riley Securities on December 19, 2024. The analyst firm set a price target for $1.50 expecting CGTX to rise to within 12 months (a possible 97.37% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Cognition Therapeutics (NASDAQ:CGTX) was provided by B. Riley Securities, and Cognition Therapeutics upgraded their buy rating.

The last upgrade for Cognition Therapeutics Inc happened on December 19, 2024 when B. Riley Securities raised their price target to $1.5. B. Riley Securities previously had a neutral for Cognition Therapeutics Inc.

The last downgrade for Cognition Therapeutics Inc happened on August 6, 2024 when B. Riley Securities changed their price target from $5 to $1 for Cognition Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognition Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognition Therapeutics was filed on December 19, 2024 so you should expect the next rating to be made available sometime around December 19, 2025.

While ratings are subjective and will change, the latest Cognition Therapeutics (CGTX) rating was a upgraded with a price target of $1.00 to $1.50. The current price Cognition Therapeutics (CGTX) is trading at is $0.76, which is out of the analyst’s predicted range.